Innovative
Biopharmaceutical Company

Based on MitoTransfer

Who We Are

PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.

Mission

PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.

MitoTransfer Therapeutics

Read more >>

Cell Therapeutics Augmented by MitoTransfer

Read more >>

Modified MitoTransfer

Read more >>

Milestone

Seoul National University Hospital Research Collaboration

2018 - NOW

Pre-series A Funding

KRW 1,5 B

Jun 2018

Series A Funding

KRW 6 B

Jun 2019

Bridge Funding

KRW 4,5 B

Jan 2021

Mitochondria GMP Facility

Jun 2021

Press Highlights

KBS 특별기획 코로나19 이후, 대한민국 길을 묻다

(주)파이안바이오테크놀로지 부분은 동영상 41-44분 참조 Source: https://vod.kbs.co.kr/index.html?source=episode&sname=vod&stype=vod&program_code=T2020-0336&program_id=PS-2021077030-01-000&broadcast_comp...

Read more >>
May 22, 2021

2021년 과학정보통신의 날 국가연구개발성과 평가부문에서 '과학기술 포장' 수상

(주)파이안바이오테크놀로지 김천형 수석부사장 과학기술포장 수상 Source: https://news.v.daum.net/v/20210421114012208?f=m

Read more >>
Apr 21, 2021

파이안바이오 "미토콘드리아 활용해 암 치료 시대 열 것"

Source: https://n.news.naver.com/article/015/0004449839

Read more >>
Nov 15, 2020